Astria Therapeutics (ATXS) Competitors

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Astria Therapeutics (NASDAQ:ATXS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk, media sentiment and community ranking.

Does the media refer more to AUPH or ATXS?

In the previous week, Aurinia Pharmaceuticals and Aurinia Pharmaceuticals both had 9 articles in the media. Aurinia Pharmaceuticals' average media sentiment score of 1.63 beat Astria Therapeutics' score of 0.99 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Astria Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders hold more shares of AUPH or ATXS?

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 99.0% of Astria Therapeutics shares are held by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are held by insiders. Comparatively, 4.5% of Astria Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has more risk & volatility, AUPH or ATXS?

Aurinia Pharmaceuticals has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, Astria Therapeutics has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500.

Do analysts prefer AUPH or ATXS?

Aurinia Pharmaceuticals currently has a consensus price target of $11.50, indicating a potential upside of 42.15%. Astria Therapeutics has a consensus price target of $30.00, indicating a potential upside of 418.13%. Given Astria Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Astria Therapeutics is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Astria Therapeutics	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.25

Which has higher earnings and valuation, AUPH or ATXS?

Astria Therapeutics has lower revenue, but higher earnings than Aurinia Pharmaceuticals. Astria Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$247.30M	4.42	-$78.02M	$0.28	28.89
Astria Therapeutics	N/A	N/A	-$72.89M	-$1.87	-3.10

Does the MarketBeat Community prefer AUPH or ATXS?

Aurinia Pharmaceuticals received 2 more outperform votes than Astria Therapeutics when rated by MarketBeat users. Likewise, 73.41% of users gave Aurinia Pharmaceuticals an outperform vote while only 73.16% of users gave Astria Therapeutics an outperform vote.

Company	Underperform	Outperform
Aurinia Pharmaceuticals	Outperform Votes 577 73.41%	Underperform Votes 209 26.59%
Astria Therapeutics	Outperform Votes 575 73.16%	Underperform Votes 211 26.84%

Is AUPH or ATXS more profitable?

Astria Therapeutics has a net margin of 0.00% compared to Aurinia Pharmaceuticals' net margin of -10.23%. Aurinia Pharmaceuticals' return on equity of -4.41% beat Astria Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	-10.23%	-4.41%	-3.07%
Astria Therapeutics	N/A	-43.58%	-29.36%

Summary

Aurinia Pharmaceuticals beats Astria Therapeutics on 9 of the 17 factors compared between the two stocks.